688161.SHG Shandong Weigao Orthopaedic Device Co. Ltd. A
- Market cap
- CNY 8.24B
- P/E
- 33.8x
- P/B
- 1.94x
- ROE
- 6.3%
- Dividend yield
- 1.55%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688161.SHG undervalued?
Graham number688161.SHG trades 70.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shandong Weigao Orthopaedic Device Co. Ltd. A fundamental analysis
No fundamental analysis for Shandong Weigao Orthopaedic Device Co. Ltd. A yet.
Shandong Weigao Orthopaedic Device Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shandong Weigao Orthopaedic Device Co. Ltd. A
Shandong Weigao Orthopaedic Device Co., Ltd. engages in research, development, production, and sales of orthopedic medical devices. The company offers orthopedic implantable medical devices and orthopedic surgical instruments. It also provides spinal products, such as internal fixation systems for the cervical and thoracic/lumbar spine, and interbody fusion devices; trauma-related products include locking plate systems, intramedullary nail systems, hollow screw systems, and …
Full company profileShandong Weigao Orthopaedic Device Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shandong Weigao Orthopaedic Device Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 1.57B | 1.82B | 2.15B | 2.06B | 1.28B | 1.45B | 1.52B | 1.41B |
| Gross Profit | 1.30B | 1.50B | 1.75B | 1.58B | 854M | 955M | 988M | 896M |
| Operating Income | 517M | 677M | 784M | 657M | 91.8M | 255M | 321M | 316M |
| EBITDA | 557M | 719M | 862M | 764M | 195M | 337M | 392M | 320M |
| Net Income | 442M | 558M | 690M | 601M | 112M | 224M | 269M | 264M |
| EPS | 1.23 | 1.56 | 1.73 | 1.50 | 0.28 | 0.56 | 0.67 | 0.66 |
| Balance Sheet | ||||||||
| Total Assets | 3.21B | 3.19B | 5.40B | 6.02B | 5.10B | 4.95B | 5.06B | 5.20B |
| Total Liabilities | 1.33B | 723M | 866M | 1.01B | 1.22B | 985M | 902M | 975M |
| Shareholders' Equity | 1.87B | 2.45B | 4.53B | 5.01B | 3.87B | 3.95B | 4.14B | 4.20B |
| Cash & Short-term Investments | 1.81B | 1.60B | 2.56B | 2.72B | 1.86B | 1.72B | 1.37B | 1.03B |
| Cash Flow | ||||||||
| Operating Cash Flow | 534M | 644M | 788M | 509M | 119M | 274M | 415M | - |
| Capital Expenditure | 28.9M | 49.6M | 112M | 116M | 43.0M | 24.3M | 27.1M | 29.3M |
| Free Cash Flow | 505M | 595M | 676M | 393M | 76.5M | 250M | 388M | 252M |
| Ratios | ||||||||
| ROE | 23.6% | 22.8% | 15.2% | 12.0% | 2.9% | 5.7% | 6.5% | 6.3% |
| ROA | 13.7% | 17.5% | 12.8% | 10.0% | 2.2% | 4.5% | 5.3% | 5.1% |
| Net Profit Margin | 28.1% | 30.6% | 32.1% | 29.2% | 8.8% | 15.4% | 17.6% | 18.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Shandong Weigao Orthopaedic Device Co. Ltd. A dividends
- Dividend yield
- 1.55%
- Forward dividend
- 0.33 CNY
- Payout ratio
- 47.5%
- Ex-dividend date
- Oct 13, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 128M | 0.32 | 47.5% |
| 2024 | CNY 75.3M | 0.19 | 33.6% |
| 2023 | CNY 164M | 0.41 | 146.0% |
| 2022 | CNY 211M | 0.53 | 35.2% |
| 2021 | - | - | - |
| 2020 | CNY 800M | 2.23 | 143.3% |
| 2019 | CNY 31.8K | 0.00 | 0.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Shandong Weigao Orthopaedic Device Co. Ltd. A
- Insiders 84.33%
- Institutions 0.33%
- Public & others 15.34%
- Shares outstanding 400M
- Free float 68.0M
Shandong Weigao Orthopaedic Device Co. Ltd. A company profile
- Company name
- Shandong Weigao Orthopaedic Device Co. Ltd. A
- Ticker
- 688161.SHG
- ISIN
- CNE1000050W9
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 1,988
- Fiscal year end
- December
- Address
- No. 26, Xiangjiang Street, Weihai, China, 264200
- Phone
- 86 63 1578 8900
- Website
- wegortho.com
About Shandong Weigao Orthopaedic Device Co. Ltd. A
Shandong Weigao Orthopaedic Device Co., Ltd. engages in research, development, production, and sales of orthopedic medical devices. The company offers orthopedic implantable medical devices and orthopedic surgical instruments. It also provides spinal products, such as internal fixation systems for the cervical and thoracic/lumbar spine, and interbody fusion devices; trauma-related products include locking plate systems, intramedullary nail systems, hollow screw systems, and external fixation systems; and joint products, including hip joint prosthesis systems, knee joint prosthesis systems, and shoulder joint prosthesis systems. In addition, the company sports medicine products comprise cruciate ligament reconstruction system, meniscus repair system, and sports trauma system; craniofacial surgery products; and orthopedic diagnostic equipment. The company was founded in 2005 and is based in Weihai, China. Shandong Weigao Orthopaedic Device Co., Ltd. operates as a subsidiary of Shandong Weigao Group Medical Polymer Co., Limited.
Shandong Weigao Orthopaedic Device Co. Ltd. A management
4- Mr. Jinqu LiGM & Director · born 1987
- Ms. Yun Lu SuCFO Accounting Supervisor & Director · born 1971
- Mr. Jian Ming KongDeputy GM & Director · born 1970
- Ms. Qing LinBoard Secretary · born 1980